Counterfeit Ozempic pens found at a US retail pharmacy

Novo Nordisk has confirmed that counterfeit versions of its diabetes drug Ozempic were found inside the legitimate U.S. pharmaceutical supply chain, at a retail pharmacy, in June 2023 ^[1]. The company said this marked the first time fake Ozempic pens had been discovered inside a real, licensed U.S. pharmacy rather than through an illegal online seller or gray-market source ^[1].

Novo Nordisk has been warning for months about a broader rise in counterfeit versions of both Ozempic and its weight-loss counterpart Wegovy, both of which contain the active ingredient semaglutide ^[1]. The company's public response to this specific finding was to urge patients to check the lot and serial numbers on their pens against the numbers on the outer carton and to compare them with information the company has published, as a way to spot pens that may not be genuine ^[1].

The sources reviewed for this story do not specify how many counterfeit pens were found, which state or pharmacy chain was involved, what was inside the fake pens, or whether any patients were harmed. Those details are not yet known based on what has been reported.

Why it matters for patients

For people using Ozempic, and by extension anyone watching the broader semaglutide market that includes Wegovy, this finding is significant because it shows counterfeits can reach patients through channels that look completely legitimate, not just through obviously suspicious online pharmacies ^[1]. A patient picking up a prescription at a normal retail pharmacy has historically had strong reason to trust that the product in the box is what it says it is. This case shows that assumption is not absolute.

Because counterfeit drugs may not contain the correct dose of semaglutide, or may contain no active ingredient at all, or could contain something else entirely, the practical risk for patients is that a fake pen may not work as expected, or could pose an unknown safety risk. The sources reviewed here do not detail what was actually found inside the fake pens in this case, so the specific danger to patients from this particular batch is not known from what has been reported.

Novo Nordisk's advice to check lot and serial numbers is a real tool patients can use, but it also puts some of the burden of verification on the patient rather than relying solely on the pharmacy or supply chain to catch problems before the product reaches consumers ^[1]. This reflects a broader pattern during a period of high demand and supply shortages for GLP-1 drugs, when counterfeiters have more incentive to try to profit from scarcity.

What happens next

The sources available for this story do not include details on any regulatory investigation, recall, or additional guidance issued by the U.S. Food and Drug Administration in response to this specific finding, nor do they indicate whether Novo Nordisk took further supply-chain security steps beyond its public warning ^[1]. It is not yet known from available reporting whether more counterfeit pens were later found in other pharmacies, or whether this incident led to changes in how pharmacies or distributors verify products before they reach patients. Readers who want to know whether their own pharmacy or pharmacy chain was affected, or what happened after this initial confirmation, should look for updated statements from Novo Nordisk or the FDA, since that information is not part of the sources reviewed here.